Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: In-vitro high-throughput gene expression study

M. Gurevich; T. Gritzman; R. Orbach; T. Tuller; A. Feldman; A. Achiron

doi:10.1016/j.jneuroim.2010.02.010

Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: In-vitro high-throughput gene expression study

M. Gurevich^*, T. Gritzman, R. Orbach, T. Tuller, A. Feldman, A. Achiron

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Laquinimod (LAQ) is a new immunomodulatory drug shown to be effective in the treatment of relapsing-remitting multiple sclerosis (RRMS); however, its molecular target pathways are not well recognized. In this study we characterized in-vitro the molecular effects of LAQ in peripheral blood mononuclear cells (PBMC) of healthy subjects and RRMS patients by gene expression microarrays. We demonstrated that LAQ induced suppression of genes related to antigen presentation and corresponding inflammatory pathways. These findings were demonstrated mainly via the NFkB pathway. Analysis of PBMC subpopulations identified activation of Th2 response in CD14+ and CD4+ cells and suppression of proliferation in CD8+ cells.

Original language	English
Pages (from-to)	87-94
Number of pages	8
Journal	Journal of Neuroimmunology
Volume	221
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2010.02.010
State	Published - Apr 2010

Keywords

Cell subpopulation
Laquinimod
Microarray gene expression
Multiple sclerosis
PBMC

Access to Document

10.1016/j.jneuroim.2010.02.010

Cite this

@article{32eda94ab7c64805b657eb9f501d4843,

title = "Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: In-vitro high-throughput gene expression study",

abstract = "Laquinimod (LAQ) is a new immunomodulatory drug shown to be effective in the treatment of relapsing-remitting multiple sclerosis (RRMS); however, its molecular target pathways are not well recognized. In this study we characterized in-vitro the molecular effects of LAQ in peripheral blood mononuclear cells (PBMC) of healthy subjects and RRMS patients by gene expression microarrays. We demonstrated that LAQ induced suppression of genes related to antigen presentation and corresponding inflammatory pathways. These findings were demonstrated mainly via the NFkB pathway. Analysis of PBMC subpopulations identified activation of Th2 response in CD14+ and CD4+ cells and suppression of proliferation in CD8+ cells.",

keywords = "Cell subpopulation, Laquinimod, Microarray gene expression, Multiple sclerosis, PBMC",

author = "M. Gurevich and T. Gritzman and R. Orbach and T. Tuller and A. Feldman and A. Achiron",

year = "2010",

month = apr,

doi = "10.1016/j.jneuroim.2010.02.010",

language = "אנגלית",

volume = "221",

pages = "87--94",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis

T2 - In-vitro high-throughput gene expression study

AU - Gurevich, M.

AU - Gritzman, T.

AU - Orbach, R.

AU - Tuller, T.

AU - Feldman, A.

AU - Achiron, A.

PY - 2010/4

Y1 - 2010/4

N2 - Laquinimod (LAQ) is a new immunomodulatory drug shown to be effective in the treatment of relapsing-remitting multiple sclerosis (RRMS); however, its molecular target pathways are not well recognized. In this study we characterized in-vitro the molecular effects of LAQ in peripheral blood mononuclear cells (PBMC) of healthy subjects and RRMS patients by gene expression microarrays. We demonstrated that LAQ induced suppression of genes related to antigen presentation and corresponding inflammatory pathways. These findings were demonstrated mainly via the NFkB pathway. Analysis of PBMC subpopulations identified activation of Th2 response in CD14+ and CD4+ cells and suppression of proliferation in CD8+ cells.

AB - Laquinimod (LAQ) is a new immunomodulatory drug shown to be effective in the treatment of relapsing-remitting multiple sclerosis (RRMS); however, its molecular target pathways are not well recognized. In this study we characterized in-vitro the molecular effects of LAQ in peripheral blood mononuclear cells (PBMC) of healthy subjects and RRMS patients by gene expression microarrays. We demonstrated that LAQ induced suppression of genes related to antigen presentation and corresponding inflammatory pathways. These findings were demonstrated mainly via the NFkB pathway. Analysis of PBMC subpopulations identified activation of Th2 response in CD14+ and CD4+ cells and suppression of proliferation in CD8+ cells.

KW - Cell subpopulation

KW - Laquinimod

KW - Microarray gene expression

KW - Multiple sclerosis

KW - PBMC

UR - http://www.scopus.com/inward/record.url?scp=77951218761&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2010.02.010

DO - 10.1016/j.jneuroim.2010.02.010

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:77951218761

SN - 0165-5728

VL - 221

SP - 87

EP - 94

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - 1-2

ER -

Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: In-vitro high-throughput gene expression study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this